Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia
Ascentage Pharma has been granted orphan drug designation (ODD) for its Bcl-2 inhibitor APG-2575 from the US Food and Drug Administration (FDA) for the treatment of Waldenström macroglobulinemia (WM). The orally administered Bcl-2 selective inhibitor that has been designed for the treatment of a range of hematologic malignancies by selectively inhibiting Bcl-2 to restore the […]